CN103356527A - Application of Sarcaboside B in medicine used for treating acute renal failure - Google Patents
Application of Sarcaboside B in medicine used for treating acute renal failure Download PDFInfo
- Publication number
- CN103356527A CN103356527A CN 201310262598 CN201310262598A CN103356527A CN 103356527 A CN103356527 A CN 103356527A CN 201310262598 CN201310262598 CN 201310262598 CN 201310262598 A CN201310262598 A CN 201310262598A CN 103356527 A CN103356527 A CN 103356527A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- renal failure
- acute renal
- application
- treating acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a new medical application of Sarcaboside B and in particular to an application of Sarcaboside B in preparation of a medicine used for treating acute renal failure. The invention discloses an application of Sarcaboside B in a medicine used for treating acute renal failure for the first time, a brand new skeleton type is adopted, and Sarcaboside B has unexpected acute renal failure treatment activity, no probability that any revelation is given by other compounds, outstanding substantial characteristic and an obvious progress when being used for treating acute renal failure.
Description
Technical field
The present invention relates to the pharmaceutical chemistry field.Particularly, the present invention relates to the novel medical use of Sarcaboside B, i.e. the application of Sarcaboside B in preparation treatment acute renal failure medicine.
Background technology
Acute renal failure (Acute Renal Failure, ARF) be the clinical syndrome that is caused by many reasons, be found in the clinical departments patient, sickness rate is high and often have serious consequences, (a few hours are to a couple of days) siddhi can sharply descend its characteristics in a short time, clinical manifestation is acute oliguria (urine amount＜400mLPd) or anuria (urine amount＜100mLPd), nitrogen matter metabolite is discharged and is produced obstacle in the body, azotemia appears rapidly, water and electrolyte, acid base imbalance, and cause each system's corresponding function imbalance of whole body.The principal element that causes acute renal failure is the rapid minimizing of renal blood flow, and because oxidative stress and the cell injury that the nephridial tissue ischemia causes finally causes the deterioration of renal tissue structural damage and function.There is no clinically at present the generally acknowledged effective medicine for the treatment of acute renal failure, only can be by correcting water-electrolyte balance, the symptomatic treatment measures such as correction acidosis improve symptom, and the later stage also needs to keep the body function by hemodialysis.There is the clinical medicine of obvious curative effects rare aspect the Renal tissues damage improving the kidney perfusion obstacle and alleviate.
The compound S arcaboside B that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes of the Sarcaboside B that the present invention relates in the anti-acute renal failure medicine of preparation, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for acute renal failure, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for simultaneously anti-acute renal failure and obviously have significant progress.
Summary of the invention
The purpose of this invention is to provide the purposes that Sarcaboside B is used for the treatment of acute renal failure, namely for the preparation of the purposes for the treatment of the acute renal failure medicine.
Sarcaboside B of the present invention has obvious therapeutical effect to the acute renal failure disease.
Research by us is found, the anuria when Sarcaboside B can improve acute renal failure or oliguria symptom, the function of protection kidney.
Described compound S arcaboside B structure is shown in formula I:
Formula I
The purposes of the Sarcaboside B that the present invention relates in the anti-acute renal failure medicine of preparation belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for acute renal failure, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for simultaneously anti-acute renal failure and obviously have significant progress.
The specific embodiment
The preparation method of compound S arcaboside B involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside B tablet involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside B capsule involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example 1 Sarcaboside B is to the therapeutical effect of acute renal failure rat
(1) experimental technique
Adopt intramuscular injection glycerol to cause the Acute Renal Failure Rats animal model.Select 60 of the healthy male SD rats of 180 ~ 220g, be divided at random 5 groups: sham operated rats (intramuscular injection normal saline); Model group (intramuscular injection glycerol); Sarcaboside B I group (0.3 mg/Kg)); Sarcaboside B II group (0.6 mg/Kg)); Sarcaboside B III group (1.2 mg/Kg)), each organizes rat immediately tail vein injection saline or Sarcaboside B after the glycerol modeling, is administered once after 12 and 24 hours again.
(2) observation index
60 rat lasts give to put into metabolic cage collection twenty-four-hour urine behind Sarcaboside B or the normal saline, stay rear 6 hours of urine with 4% chloral hydrate intraperitoneal injection of anesthesia, adopt laser Doppler flowmetry to measure after the modeling and the rear bilateral renal blood flow for the treatment of, average as single animal renal blood flow; Get blood and prepare serum, measure blood BUN and Cre; Get kidney, prepare 10% renal cortex homogenate, measure renal cortex homogenate MDA, GSH, NO(all by the operation of test kit description).
(3) experimental result
1. Sarcaboside B can increase acute renal failure Mouse Kidney blood flow
Table 1 Sarcaboside B is on the impact of acute renal failure Mouse Kidney blood flow
* P＜0.05vs acute renal failure model group
2. Sarcaboside B is to the protective effect of acute renal failure Mouse Kidney function tool
The model group rat significantly reduces than rats in sham-operated group twenty-four-hour urine amount, is respectively 4.57 ± 0.74ml and 11.82 ± 2.36ml; Middle and high dosage Sarcaboside B group twenty-four-hour urine amount is significantly higher than model group (P＜0.05), and the urine measurer of three medication therapy groups has dose dependent, is respectively I group 5.42 ± 0.86ml, II group 7.86 ± 1.37ml, III group 9.66 ± 1.59ml.Illustrate that Sarcaboside B can improve the oliguria symptom of acute renal failure rat.
Acute renal failure rat intravenous injection normal saline is after 24 hours, and serum BUN is 25.53 ± 1.62mmol/L, and Cre is 168.56 ± 13.01umol/L, apparently higher than sham operated rats, illustrates that model group animal renal function injury is serious.Middle and high dosage Sarcaboside B can improve the renal function (P＜0.05) of acute renal failure rat in dose dependent ground.See Table 2.
Each rats in test groups renal function index of table 2 relatively
* P＜0.05vs acute renal failure model group
Conclusion: the anuria when Sarcaboside B can improve acute renal failure or oliguria symptom, the function of protection kidney can be used for preparing anti-acute renal failure medicine.
Claims (1)
1.Sarcaboside the application of B in treatment acute renal failure medicine, described compound S arcaboside B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262598 CN103356527A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating acute renal failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262598 CN103356527A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating acute renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356527A true CN103356527A (en) | 2013-10-23 |
Family
ID=49359349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310262598 Pending CN103356527A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating acute renal failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356527A (en) |
-
2013
- 2013-06-27 CN CN 201310262598 patent/CN103356527A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| CN102872115B (en) | Application of Houttuynoid A in preparing medicament for treating acute renal failure | |
| CN103599102B (en) | Application of Nitrosporeusines A in drugs for treating acute renal failure | |
| CN102872094A (en) | Application of Houttuynoid B in medicine for treating acute renal failure | |
| CN102861095B (en) | Application of Houttuynoid E in medicine for treating acute renal failure | |
| CN102861008A (en) | Application of Aphanamixoid A in medicine for treating acute renal failure | |
| CN102872140B (en) | Application of Houttuynoid C in drug for treating acute renal failure | |
| CN103356605B (en) | Application of Chukrasone B in preparing medicines for treating acute renal failure | |
| CN103127151A (en) | Application of Gypensapogenin A in medicines treating acute renal failure | |
| CN103356527A (en) | Application of Sarcaboside B in medicine used for treating acute renal failure | |
| CN103356543A (en) | Application of Sarcaboside A in preparation of drug for treating acute renal failure | |
| CN103251637A (en) | Application of Polyflavanostilbene A in preparing medicine for treating acute renal failure | |
| CN103356646B (en) | The application of Chukrasone A in preparation treatment acute renal failure medicine | |
| CN102872097A (en) | Application of Houttuynoid D in medicine for treating acute renal failure | |
| CN103520172B (en) | The application of Kadcoccitones A in preparation treatment acute renal failure medicine | |
| CN103127069A (en) | Application of Eryngiolide A in medicines treating acute renal failure | |
| CN103462996A (en) | Application of Neonectrolide A in preparing medicament for treating acute renal failure | |
| CN103599105B (en) | Application of Caesanines D in drugs used for treating acute renal failure | |
| CN103446119B (en) | Application of Fluevirosines A in preparation of acute renal failure treating drug | |
| CN102895242A (en) | Application of Gypensapogenin B in drugs for treating acute renal failure | |
| CN103655538B (en) | The application of Hippolachnin A in treatment acute renal failure medicine | |
| CN103463009A (en) | Application of racemosins A in preparation of medicine treating acute renal failure | |
| CN105078954A (en) | Medicine for treating acute renal failure and application thereof | |
| CN105456238A (en) | Application of Norsampsone A in preparation of drug for treating acute renal failure | |
| CN103340877A (en) | Application of Aspeverin in preparation of medicine for treating acute renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |